- Conditions
- AL Amyloidosis
- Interventions
- Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
- Interventions
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
- Biological · Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- lintuzumab, lenalidomide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- COVID-19, Coronavirus Infection, Corona Virus Infection
- Interventions
- Blood draw
- Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma
- Interventions
- iratumumab
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • New York, New York • Columbus, Ohio
- Conditions
- HER2 Positive Solid Tumors
- Interventions
- SBT6050, pembrolizumab, Cemiplimab
- Drug
- Lead sponsor
- Silverback Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Kidney Cancer
- Interventions
- girentuximab, placebo
- Biological · Other
- Lead sponsor
- Heidelberg Pharma AG
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 39
- States / cities
- Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- efalizumab
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 47 more
- Conditions
- Healthy Volunteer
- Interventions
- BMS-986446 IV, BMS-986446 SC, Acetaminophen, Loratadine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Anaheim, California
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Secukinumab 300 mg, Placebo
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more
- Conditions
- Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Interventions
- tafasitamab, parsaclisib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
- Interventions
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- isatuximab SAR650984 IV, pomalidomide, dexamethasone, isatuximab SAR650984 SC, Investigational injector device
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Gilbert, Arizona • Duarte, California • Canton, Ohio
- Conditions
- Contraception
- Interventions
- ZB-06
- Biological
- Lead sponsor
- KBio Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Advanced Cancer
- Interventions
- Cohort 1 anti-OX40, Cohort 2 anti-OX40, Cohort 3 anti-OX40, Tetanus Day 29, Tetanus Day 1, KLH Day 1, KLH Day 29
- Drug · Biological
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Head and Neck Cancer
- Interventions
- Retifanlimab, INCAGN02385, INCAGN02390, Placebo
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
- Interventions
- BGB-A445, tislelizumab
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Diego, California • Pittsburgh, Pennsylvania
- Conditions
- Prevention of HIV Infection, HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody
- Interventions
- VRC-HIVMAB080-00-AB (VRC01LS), VRC-HIVMAB060-00-AB (VRC01)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV-1 Infection
- Interventions
- VRC07-523LS, Vorinostat (VOR)
- Biological · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Golimumab, Placebo, methotrexate (MTX)
- Drug · Other
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 9
- States / cities
- Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more
- Conditions
- Colorectal Cancer
- Interventions
- monoclonal antibody hu3S193
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- -Unhealthy Children With a History of Prematurity
- Interventions
- MEDI-493
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 5 Months to 6 Months
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Parkinson's Disease (PD)
- Interventions
- TB006, Placebo
- Drug
- Lead sponsor
- TrueBinding, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Aliso Viejo, California • Palo Alto, California • Englewood, Colorado + 11 more